Shares of Nektar Therapeutics (NASDAQ:NKTR) have received an average recommendation of “Hold” from the nineteen brokerages that are presently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $29.00.
NKTR has been the subject of a number of analyst reports. Oppenheimer initiated coverage on shares of Nektar Therapeutics in a research note on Thursday, October 24th. They issued a “market perform” rating and a $18.00 price objective for the company. BidaskClub downgraded shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 30th. BMO Capital Markets dropped their target price on shares of Nektar Therapeutics from $75.00 to $41.00 and set an “outperform” rating on the stock in a report on Friday, August 9th. Cfra set a $35.00 target price on shares of Nektar Therapeutics and gave the stock a “hold” rating in a research report on Friday, August 9th. Finally, Canaccord Genuity upped their price target on shares of Nektar Therapeutics from $20.00 to $24.00 and gave the company a “buy” rating in a report on Tuesday, November 12th.
In other Nektar Therapeutics news, major shareholder Katharina Otto-Bernstein sold 29,127 shares of the company’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $36.72, for a total value of $1,069,543.44. Also, CFO Gil M. Labrucherie sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $20.52, for a total value of $513,000.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 175,178 shares of company stock valued at $3,738,898. Insiders own 4.02% of the company’s stock.
Hedge funds have recently made changes to their positions in the business. NEXT Financial Group Inc acquired a new stake in Nektar Therapeutics during the second quarter worth $137,000. Commonwealth Equity Services LLC boosted its position in shares of Nektar Therapeutics by 11.4% during the 2nd quarter. Commonwealth Equity Services LLC now owns 26,813 shares of the biopharmaceutical company’s stock valued at $954,000 after acquiring an additional 2,738 shares in the last quarter. Commerzbank Aktiengesellschaft FI acquired a new stake in shares of Nektar Therapeutics during the 2nd quarter valued at about $949,000. First Quadrant L P CA increased its stake in Nektar Therapeutics by 426.9% in the second quarter. First Quadrant L P CA now owns 44,103 shares of the biopharmaceutical company’s stock valued at $1,569,000 after acquiring an additional 35,733 shares during the period. Finally, Traynor Capital Management Inc. increased its stake in Nektar Therapeutics by 401.8% in the second quarter. Traynor Capital Management Inc. now owns 35,250 shares of the biopharmaceutical company’s stock valued at $1,263,000 after acquiring an additional 28,225 shares during the period. Institutional investors own 99.77% of the company’s stock.
NKTR traded up $0.59 on Tuesday, hitting $20.45. The company had a trading volume of 2,285,319 shares, compared to its average volume of 2,417,347. The company’s fifty day moving average price is $18.91 and its 200 day moving average price is $24.52. Nektar Therapeutics has a 1-year low of $15.64 and a 1-year high of $47.11. The company has a debt-to-equity ratio of 0.26, a current ratio of 12.60 and a quick ratio of 12.49. The stock has a market cap of $3.57 billion, a price-to-earnings ratio of 5.41 and a beta of 2.61.
Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.17. The firm had revenue of $29.22 million during the quarter, compared to analysts’ expectations of $26.42 million. Nektar Therapeutics had a negative return on equity of 26.60% and a negative net margin of 352.83%. The company’s revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.56) earnings per share. On average, sell-side analysts forecast that Nektar Therapeutics will post -2.56 EPS for the current year.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.
Read More: Quick Ratio
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.